The bone mass was measured by dual energy X-ray absorptiometry in 25 survivors of childhood leukaemia or lymphoma (21 with ALL) who had received TBI and allogeneic BMT a median of 8 years ago (range 4-13).
During the last decades the survival rates after childhood leukaemia and lymphoma have improved considerably. 1 For children with very high risk 2 or relapsed disease, [3] [4] [5] allogeneic BMT with a related donor will give the highest chance of survival. Unfortunately, allogeneic BMT for childhood cancer has frequent and severe delayed sideeffects. These include reduced growth 6 and final height, 7, 8 disturbed pubertal development, 6 reduced fertility, 9 and impaired cardiac 10 and pulmonary function. Reduced growth caused by impaired growth hormone (GH) secretion is a frequent complication of cranial or total body irradiation for childhood cancer. 6, 12 Patients with reduced GH secretion frequently have reduced bone mass, 13 Correspondence: Dr K Nysom, Kurvej 16, DK-2880 Bagsv rd, Denmark Received 21 June 1999; accepted 19 September 1999 which increases their risk for osteoporotic fractures.
14 In addition, most children treated for leukaemia or lymphoma receive corticosteroids and MTX. Long-term corticosteroid therapy causes reduced bone mass and increases the risk of osteoporotic fractures; 15 MTX may have the same effects. [16] [17] [18] [19] Growth and endocrine function after BMT for childhood cancer have been studied extensively. [6] [7] [8] In contrast, the bone mass after BMT has only been studied in small groups of patients who were nearly all transplanted in adulthood. [20] [21] [22] [23] [24] [25] In the only previous paper on the bone mass after BMT in childhood or adolescence, Bhatia et al 23 recently reported reduced whole-body bone mass 2 years after BMT for myeloid leukaemia. The study was limited by few participants and by lack of local control data for the bone mass of both healthy subjects and untransplanted survivors of childhood myeloid malignancies.
We studied the bone mass of 25 patients several years after allogeneic BMT for childhood leukaemia or lymphoma. Results were compared with the bone mass of 463 healthy local controls and 95 childhood ALL survivors in first remission treated without BMT. 26 The three groups were all examined with the same scanner.
Patients and methods

Patients
Before 31 December 1990, 43 patients had been treated with allogeneic BMT for haematological malignancies diagnosed before the age of 15 while they resided in East Denmark. Twenty-five (86%) of the 29 patients who were alive in January 1992 (survival 67%) gave informed consent to participate in the present study. Twenty-one participants had ALL, two AML, one CML, and one T cell nonHodgkin's lymphoma. Seven participants received BMT in first remission, 14 in second remission, three in third remission, and one in first chronic phase of CML. All participants had been treated with multiagent chemotherapy as described previously:
11 all but one received corticosteroids in a median cumulative dose of 7.3 g/m 2 of prednisone (range 0. 8-28.4) . Doses of corticosteroids other than prednisone were corrected to prednisone equivalent doses. Nineteen participants received oral MTX in a median cumulative dose of 1.6 g/m 2 (0.1-5.2) and 16 participants received a median of three high-dose MTX infusions (range [1] [2] [3] [4] [5] [6] [7] [8] . Thirteen participants received cranial irradiation, three of these received additional spinal irradiation, and 12 of 13 males received testicular irradiation as described previously. 7 The median age of the participants was 6.9 years at diagnosis (1.9-15.0), 11.3 years at BMT (5.7-17.6), and 17.2 years at time of the study (11.3-26.5) . The median length of follow-up was 10.5 years from diagnosis (5.1-22.8) and 7.5 years from BMT (3.6-12.6). Twelve of the 25 participants developed acute GVHD of grade 2 or more, 27 while none suffered from chronic GVHD. Two participants had symptoms and signs in accordance with avascular necrosis of bone. During induction therapy, one participant had a cerebral vascular thrombosis, which resulted in a paresis of his right leg. He had not recovered completely at follow-up.
All four non-participants had ALL. They did not differ significantly from the participants for age at diagnosis, age at BMT, type of marrow donor, or frequency of acute GVHD of grade 2 or more. However, three of four nonparticipants had severe chronic GVHD, and one of these died of lung insufficiency after he had been invited to participate in this study.
Conditioning regimen, BMT and supportive care
All participants were conditioned for BMT with 120 mg/kg of cyclophosphamide and TBI. Four received 8.5 Gy (8.0-8.5) and two received 10 Gy, both in one fraction at a dose rate of 0.060 Gy/min. All other participants received 11.3 Gy (10.9-11.7) in three fractions at a dose rate of 0.088 Gy/min. 11 Total dose was measured by in vivo dosimetry. Seventeen participants received marrow from a HLA-identical sibling, while the rest received marrow from other family donors. Patients with a HLA-identical sibling donor received cyclosporine A for GVHD prophylaxis, routinely for 6 months. The other patients in addition received three doses of MTX intravenously. One patient received seven doses of MTX intravenously, but no cyclosporine A. The donor marrow was not T cell-depleted. Glucocorticoids and, in some cases, anti-thymocyte globulin were used to treat GVHD. Supportive treatment during BMT included skin and gastrointestinal decontamination, laminar air flow isolation, and prophylactic sulphamethoxazole and trimethoprim for 6 months.
Bone mineral assessment
Bone mineral content (BMC), anterior-posterior projected bone area, and bone mineral areal density (BMC divided by bone area, BMD A ) were determined by dual-energy Xray absorptiometry using a Hologic 1000/W (Hologic, Waltham, MA, USA). Bone mineral values for the whole body and the lumbar spine subregion were derived from wholebody scans. BMD A of the lumbar vertebrae L 1 -L 4 was also measured by dedicated lumbar spine scans. For quality control, a spine phantom was scanned daily. During the study period, the coefficient of variation for these BMC, bone area and BMD A measurements (n = 137) was 0.37%, 0.27% and 0.34%, respectively.
Bone mineral measurements derived from whole-body scans, as well as heights, were compared with local reference values for children and adolescents (n = 343, age 6-19 years 28 ) or young adults (n = 120 (40 men), age 20-38 years, C Mølgaard, unpublished data). The latter group consisted of healthy staff members or university students and follow-up of 41 adolescents examined by us previously 28 29 Therefore, for lack of local reference data, BMD A values from dedicated lumbar spine scans were compared with device-specific reference values supplied by the manufacturer (Hologic). Bone mineral measurements were also compared with the bone mass of 95 survivors of childhood ALL who were in first remission a median of 11 years (range 3-23) after diagnosis, who had never been irradiated outside a cranial field, and who had not been treated with BMT. 26 
Hormone assessment
The GH axis was tested as described previously. 7 Blood samples for the analysis of oestradiol (females) or testosterone (males) were drawn during the same procedure at baseline, analysed as described previously, 30 and compared with local reference values (Ref. 30 and A Juul et al, unpublished data, January 1998). At follow-up, four participants (three males) received GH therapy, 11 (three males) received sex hormone therapy, and three (one male) received thyroxine. 7 Two participants had received GH therapy previously for 5 and 33 months.
Calcium intake assessment
Participants were interviewed about their habitual daily intake of various dairy products, and their daily intake of calcium through dairy products was estimated. Average adult Danes consume 75% of their calcium intake as dairy products, 31 and participants were classified as having a sufficient calcium intake if their daily intake of dairy products contained 75% of their recommended daily calcium intake.
Data analysis
Results were analysed as age-and sex-specific z scores. Whole-body bone mineral measurements were also analysed in a three-step approach suggested by us recently, 28 based on sex-specific z scores for height for age, bone area for height and BMC for bone area. All z scores were based on smoothed modelling of the control data with the LMS method of Cole and Green. 32 Bone area for height and BMC for bone area z scores were furthermore adjusted to account for the covariation of these z scores with weight (bone area for height) and age below or above 20 years (bone area for height and BMC for bone area) among the healthy controls.
The distribution of height and bone mineral z scores did not differ significantly from a normal distribution (ShapiroWilk test); therefore these results are expressed as mean values with 95% confidence intervals (CI). All other data are reported as median values with ranges. A t-test was used to test for mean z scores different from 0 and to test for different mean z scores in two groups. Fisher's exact test was used to compare categorical data among groups of patients. Simple and multiple linear regression was used to examine the relationship between bone mass (in z scores) and previous therapy, sex, age at BMT, length of follow-up, estimated calcium intake, and endocrine status at followup. Probabilities below 0.05 were considered statistically significant. Participants were classified as having sufficient or insufficient GH secretion. 7 Data were analysed with SAS computer software. 33 
Ethics
All patients and the parents of the children younger than 18 gave written informed consent. The study was in accordance with the Helsinki II declaration and was approved by the local medical ethics committee of Copenhagen and Frederiksberg, Denmark (approval No. KF V92-097).
Results
Compared with healthy controls, the mean whole-body BMC and BMD A were both significantly reduced (z = −0.78, CI −1.20 to −0.36 and z = −0.54, CI −0.97 to −0.11). The reduced whole-body BMC was caused by a significantly reduced height for age (z = −0.86, CI −1.32 to −0.40), whereas bone area for height and BMC for bone area did not differ significantly from that of healthy controls (z = 0.28, CI −0.12 to 0.69 and z = 0.07, CI −0.47 to 0.61). In the lumbar spine, the mean BMD A determined by a dedicated scan was significantly reduced (z = −0.47, CI −0.91 to −0.03) whereas BMC and BMD A derived from wholebody scans were not (z = −0.42, CI −0.91 to 0.08 and z = −0.25, CI −0.79 to 0.28). Figure 1 shows how whole-body BMC, height, bone area for height and BMC for bone area varied with sex, additional cranial irradiation and age at follow-up. The bone mass tended to be less in older patients and in patients treated with additional cranial irradiation. Table 1 gives details on multiple regression models for height and bone mass. Less whole-body bone mass in the older participants was caused by a tendency to less BMC for bone area. Less bone mass in patients treated with additional cranial irradiation was caused by lower height (Table 1, Figure 1) . GH deficiency at follow-up tended to be more frequent in patients treated with additional cranial irradiation than in the remaining patients (seven of 13 vs two of 12, P = 0.10). In accordance with this, multiple regression models based on age at follow-up and GH status gave results very similar to those in Table 1 (data not shown). Controlled for age at follow-up, GH status and additional cranial irradiation were never significant in the same models (data not shown).
Controlled for additional cranial irradiation and age below or above 20 years at follow-up, the whole-body BMC and BMD A were not significantly related to sex (P = 1.0), additional spinal irradiation (P = 0.4 and 0.5), the Bone Marrow Transplantation cumulative doses of corticosteroids or peroral MTX (P = 0.5-0.7), the number of high-dose MTX infusions (P = 0.13 and 0.09, tending to relate less bone mass to fewer infusions), age at BMT (P = 0.4), unfractionated TBI (P = 0.9 and 1.0), length of follow-up after BMT (P = 0.8 and 0.7), reduced sex hormone secretion at follow-up (P = 0.5 and 0.9), or calcium intake at follow-up (P = 0.08-0.9, tending to relate less bone mass to higher calcium intake). Thirteen patients had a reduced sex hormone secretion at follow-up and nine reported a calcium intake below that recommended.
Controlled for age below or above 20 years at followup, BMC for bone area did not tend to be related to sex, additional cranial irradiation, the cumulative doses of corticosteroids or peroral MTX, the number of high-dose MTX infusions, age at BMT, length of follow-up after BMT, or endocrine status at follow-up (P = 0.6-1.0). Controlled for age below or above 20 years at follow-up, BMC for bone area tended to be less in patients with a calcium intake above that recommended (P = 0.08).
Controlled for additional cranial irradiation and age below or above 20 years at follow-up, there was only a weak tendency to slightly less whole-body bone mass in patients treated with allogeneic BMT than in 95 ALL survivors in first remission treated without BMT (estimated difference in BMC 0.27, CI −0.20 to 0.74; BMD A 0.08, CI −0.38 to 0.54). In accordance with this, height for age, bone area for height, and BMC for bone area did not tend to differ between BMT patients and ALL controls (P = 0.4-0.5). Estimates of the difference between BMT patients and ALL controls were only minimally altered if the models also controlled for sex (data not shown).
Discussion
Compared with healthy controls, the whole-body bone mass was slightly but significantly reduced a median of 8 years after TBI and allogeneic BMT for childhood leukaemia or lymphoma. This was caused by a significantly reduced height, whereas bone area for height and BMC for bone area did not differ significantly from that of controls. Less whole-body bone mass tended to be related to age above 20 years at follow-up and either additional cranial irradiation or GH deficiency at follow-up. Controlled for age at follow-up and previous cranial irradiation, the wholebody bone mass tended to be only marginally less after BMT than after childhood ALL treated without BMT.
Reduced bone mass may be caused by reduced bone size, reduced size-adjusted bone mass, or both. BMC or BMD A can, however, not distinguish between these causes. It is particularly complicated to evaluate the mechanism of reduced bone mass in growing subjects. 34 Useful approaches include BMC adjusted for bone area, height, and weight; 34 bone mineral volumetric density; 35 and BMC adjusted stepwise for height and bone area. 28 Bhatia et al 23 recently reported reduced whole-body BMD A a median of 2 years after BMT for childhood AML (n = 9) or CML (n = 1). Eight BMTs were allogeneic and most patients were conditioned without TBI. The study was limited by few participants and lack of local control data for Bone Marrow Transplantation Figure 1 Height and bone mass after allogeneic BMT for childhood leukaemia or lymphoma. Whole-body BMC for age, height for age, bone area for height, and BMC for bone area in z scores plotted against age at follow-up. Boxes indicate males, circles females. Open symbols indicate patients treated without additional cranial irradiation, filled symbols patients treated with additional cranial irradiation.
Table 1
Multiple regression models for height and bone mass the bone mass of both healthy subjects and untransplanted survivors of childhood myeloid malignancies.
To the best of our knowledge, the present paper is the first one to report the bone mass of a larger group of patients treated with allogeneic BMT for childhood ALL. Nussey et al 36 included five patients treated with TBI and allogeneic BMT in a group of 10 childhood ALL survivors who had GH deficiency and had been treated with GH. On average, the group had normal lumbar spine and femoral BMD A , but the five BMT survivors were not analysed separately.
Lumbar spine BMD A was reduced after allogeneic BMT for adult-onset malignancies. [20] [21] [22] Most women had ovarian insufficiency but did not receive hormone replacement therapy, and BMD A increased after onset of hormone replacement therapy. 21 Lumbar spine and hip BMD A and wholebody BMC all decreased in adults after allogeneic BMT despite most women receiving hormone replacement therapy. 24, 25 Whole-body BMC decreased to the same extent after autologous and allogeneic BMT, whereas lumbar spine and hip BMD A decreased after allogeneic BMT only. 25 Recently, we reported reduced whole-body bone mass in 95 childhood ALL survivors in first remission and related this to cranial irradiation and older age at follow-up. 26 With that group as a reference, we could indirectly estimate the impact on the bone mass of a relapse of leukaemia, a second induction therapy, an allogeneic BMT, and the resulting variety of complications. Remarkably, controlled for cranial irradiation and age at follow-up, the bone mass differed minimally between BMT survivors and untransplanted ALL controls. This may partly be caused by the incidental absence of chronic GVHD in our participants, or by less intensive initial therapy to the BMT patients than to the ALL controls.
The slightly reduced bone mass of our patients seemed to be caused by reduced height, which was related to additional cranial irradiation. Reduced height after allogeneic BMT for childhood leukaemia or lymphoma is caused by cranial irradiation and its endocrine and anthropometric sequelae, 12 radiation damage to bone growth zones, 6, 8, 37 and maybe GVHD. 6, 38 Overall, the size-adjusted bone mass of our patients was normal; it may be slightly less in the young adults than in the children and adolescents ( Table 1) . As in the ALL controls, 26 the size-adjusted bone mass of our participants was not related to any other treatment or patient characteristics. This is in contrast to Gilsanz et al, 35 who found less lumbar spine bone mineral volumetric density in childhood ALL survivors after cranial irradiation.
In the present study, the bone mass was mainly reduced in adults, who may attain less peak bone mass than others and/or may lose bone mass faster than others. Impaired attainment of peak bone mass is likely after BMT for childhood leukaemia or lymphoma, because GH deficiency of childhood onset impairs the accretion of bone mass 39, 40 and TBI impairs final height in spite of GH therapy. 8 It is unknown whether GH deficient adults lose bone mass faster than normal. Previously, GH therapy was stopped after final height had been reached, even though peak bone mass is not attained until several years, maybe a decade later. 41, 42 However, if patients meet the criteria agreed upon by an international board, 43 continued GH replacement is now offered in many countries, and this may reduce the risk for clinically significant osteoporosis. Adequate sex hormone levels are necessary to accumulate and maintain bone mass. 13, 21, 44, 45 Sex hormone secretion was, however, not related to bone mass in our study, probably because all but two participants with reduced sex hormone secretion received replacement therapy.
Osteoporotic fractures mainly occur in post-menopausal women, in whom the risk for fracture increases with less whole-body BMC or BMD A . 46 The relationship between size-adjusted whole-body bone mass and osteoporotic fractures is unknown. No firm data are available on whether the pattern of reduced whole-body bone of our participants (reduced height, normal size-adjusted bone mass) increases their risk for osteoporotic fractures: less whole-body BMC increases the risk for a new hip fracture 46 but shorter persons are at reduced risk for hip fractures. 47, 48 Anyway, if survivors of BMT for childhood leukaemia or lymphoma lose bone mass faster than normal because of GH or sex hormone deficiency, they will have an excess risk for fracBone Marrow Transplantation tures later on, and, consequently, these patients should receive adequate hormone replacement therapy.
Our group of participants should be a non-biased sample of survivors of BMT for childhood leukaemia or lymphoma, except that none had chronic GVHD. One participant had a partly paretic leg, which may explain his reduced bone mass, but when he was excluded from the analysis, conclusions were essentially the same.
In conclusion, 8 years after TBI and allogeneic BMT for childhood leukaemia or lymphoma, the whole-body bone mass was only slightly reduced and the size-adjusted bone mass was normal.
